An NCI-designated Comprehensive Cancer Center

Tina Wang, M.D.

Medical Oncologist
Clinical Expertise
  • Breast, Lung, Liver
  • Immunotherapy
Assistant Clinical Professor, Department of Medical Oncology and Therapeutics Research
South Pasadena Patients: 877-998-7546
Other Languages Spoken
  • Mandarin
I am excited to make cutting edge cancer care accessible to patients in the local community clinics.

Tina Wang, M.D. began thinking about a career in medicine and oncology while still in high school, when a family friend passed away from lymphoma. “As I started to study more about the biology of cancer, I became much more interested in how cancer grows and ways to stop the growth,” she says.

Dr. Wang specializes in breast, liver and lung cancer, with a particular focus on recent advances in immunotherapy. She is board certified in hematology, oncology, and internal medicine.

An honors student from Stanford University, Dr. Wang received her medical degree at the University of Texas, where she was a member of the Alpha Omega Alpha Honor Society. She completed her residency and fellowship at UCLA. She also did immunology research at MD Anderson Cancer Center in Houston, TX. Prior to joining City of Hope, she was an assistant professor at UCLA.

Dr. Wang puts a high priority on building relationships with her patients. She is also passionate about serving the larger community as a lecturer and educator in both English and Mandarin.


209 Fair Oaks Ave.

South Pasadena, CA 91030

301 W. Huntington Drive, Suite 400

Arcadia, CA 91007


Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, M, Hunt J, Wolf B, Jones B, Madrigal J, Garon EB. “A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC,” Journal of Thoracic Oncology, in press.

Hsu M, Sedighim S, Wang T, Everson E, Tucker A, Antonios J, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong W, Davidson T, Gang L, Liau L, Prins R. “TCR sequencing can identify and track tumor-specific T cell populations and is a predictive biomarker of response to DC vaccination in glioblastoma patients,” Cancer Immunology Research, 2016, May.

Rawal S, Chu F, Kannan S, Zhang M, Percivalle E, Delgado D, Chou T, Sharma R, Davis R, Neelapu S. “Cross talk between follicular helper T cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment,” Journal of Immunology, 2013 June.

Chou T, Finn RS, Garon EB. “Expanding Options for EGFR Targeting in Lung Cancer,” Translational Lung Cancer Research, 2012 Dec.

Chou T, Finn RS. “Brivanib: a review of development,” Future Oncology, Sept 2012.

G. Trapp, K. Sydow, M. T. Dulay, T. Chou, J. P. Cooke, and R. N. Zare, "Capillary Electrophoretic and Micellar Electrokinetic Separations of Asymmetric Dimethyl-L-arginine and Structurally Related Amino Acids: Quantitation in Human Plasma," J. Sep. Sci. 2004 Dec.


Wang T. “Breast Cancer Survivorship.” Huntington Hospital and Herald Cancer Association 12th Annual Pink Ribbon Conference, Oct 2018. Lecture presentation.

Lisberg A, Hunt J, Reese N, Wang T, Goldman J, Garon E. “A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients with Advanced NSCLC.” IASLC 17th Annual Targeted Therapies of the Treatment of Lung Cancer, February 2017. Poster presentation.

Wang T. “Cancer Care in the Elderly.” Alhambra Hospital Medical Center 10th Annual Geriatric Symposium, November 2016. Lecture presentation.

Chou T, Pietras R, Goodglick L, Garon E. “Phase I dose escalation study of carboplatin, pemetrexed and exemestane in post-menopausal women with metastatic non-squamous NSCLC.” UCLA Solomon Scholars Research Day, June 2012. Poster presentation.

In The News